Metagenomi Therapeutics, Inc. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Metagenomi released a corporate presentation detailing its lead program MGX-001, an in vivo CRISPR gene editing therapy for hemophilia A. The company reported completing a pre-IND interaction with the FDA in December 2025 with a favorable outcome, with IND submission targeted for Q4 2026 and first patient dosing in 2027. Preclinical data in non-human primates demonstrated durable Factor VIII expression over ~19 months, achievement of curative FVIII levels, and a favorable safety profile; the company has $120.7M in cash at end of Q2 2026 with runway through Q4 2027.
Why this rating
Lead program advancing to clinic is significant for $51M company; favorable FDA feedback and durable preclinical data are encouraging but clinical success unproven; adequate cash runway reduces near-term dilution risk.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.